Milestone Pharmaceuticals Inc (MIST NASDAQ) stock market data APIs
$1.8459
0.11(6%)
as of June 27, 2025
Try our APIs with
free plan!
Milestone Pharmaceuticals Inc Financial Data Overview
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Prev. Close
1.8459
Open
1.9585
High
2.0386
Low
1.8455
52 wk Range
0.625-2.75
Market Cap
99 444 K
Shares Outstanding
53 464 K
EPS
-0.31
Beta
0.917
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Milestone Pharmaceuticals Inc data using free add-ons & libraries
Get Milestone Pharmaceuticals Inc Fundamental Data
Milestone Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -52 045 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.195
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Milestone Pharmaceuticals Inc News
New
Milestone Pharma Announces Submission Of Its Response To CRL Regarding NDA For CARDAMYST
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced submission of its response to the FDA's Complete Response Letter regarding its New Drug Application for CARDAMYST nasal spray, a prescriptio...
Milestone Pharmaceuticals submits response to FDA for PSVT drug
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a $109.52 million market cap biotech company trading at $1.65 per share, has submitted its response to the U.S. Food and Drug Adminis...
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) --...
FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
